Posts

When Winning Isn't Enough: Edinburgh Worldwide, Bain Capital Korea, and the Structural Logic of Relational Risk

■ The Edinburgh Paradox Edinburgh Worldwide Investment Trust (EWI), managed by Baillie Gifford, has defeated Saba Capital Management at the ballot box twice. In January 2026, 53.2% of shareholders voted to retain the incumbent board, and over 90% of non-Saba shareholders rejected Saba's nominees. Yet in April 2026, EWI's board is proposing a 100% exit tender offer — effectively winding down a 28-year-old institution. The board has warned there is a "high probability" that Saba wins control at the April 30 AGM. How does a twice-defeated activist maintain the ability to threaten corporate dissolution? The answer is structural, not transactional. ■ Relational Architecture, Not Vote Counts Saba Capital holds 31% of EWI's shares. That is not a financial position — it is a persistent structural presence in the governance network. No individual vote can neutralize the permanent relational authority of a 31% block. Every resolution, every strategy, every board appointment...

CVC's Recordati $12.7 billion Mega LBO

  Review of Private Equity, Pharmaceutical, Infrastructure Privatization, and Relationship Risks CVC's Recordati $12.7 billion Mega LBO Relational Risk Research Institute | Research Session | 2026-04-10 Participating Researchers: Warren (Economist) Sam (AI Specialist) Phill (Social Philosopher) Key figures $12.7bn CVC's acquisition of Recordati deal size Equity $6.4–7.0bn + Debt $5.7–6.3bn 6.7 times Debt / EBITDA Leverage Ratio Exceeding the safety zone standard of 4.5 times +34% Average drug price increase rate within 3 years after PE acquisition R&D investment decreased by an average of 18% during the same period. Deal Structure Overview item Number / Content Transaction volume $12.7bn (approximately 17.2 trillion won) Equity injection $6.4–7.0 billion (leverage ratio approx. 45–50%) debt financing $5.7~6.3bn EV / EBITDA multiple Approximately 14 times (based on EBITDA €900M) Debt / EBITDA 6.7x — Moody's Pharmaceuticals LBO exceeds safety zone (4.5x) Joint investor co...